amerisourcebergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain and enhance patient care. as the leader in global sourcing and distribution, we source and distribute brand, generic, specialty, otc pharmaceuticals and other healthcare products. we increase the effectiveness and efficiency of your supply chain by ensuring products are delivered securely, consistently and cost-effectively, improving product access for pharmacies, providers and patients. our pharmacy solutions result in greater operational efficiency, cost control, growth opportunities and patient safety. our provider solutions drive operational efficiency, financial performance and improve quality of care. our manufacturer solutions maximize success at every stage of the product lifecycle. amerisourcebergen. where knowledge, reach and partnership shape healthcare delivery.
Company profile
Ticker
COR
Exchange
Website
CEO
Steven Collis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERISOURCE BERGEN CORP, AMERISOURCEBERGEN CORP
SEC CIK
Corporate docs
Subsidiaries
AB Singapore Investments Pte Ltd • AB UK Holdings Ltd • AH UK Holdco 1 Ltd • Amerisource Receivables Financial Corporation • AmerisourceBergen Drug Corporation • AmerisourceBergen Global Holdings GmbH • AmerisourceBergen Global Manufacturer Services GmbH • AmerisourceBergen Group GmbH • AmerisourceBergen International B.V. • AmerisourceBergen International Holdings Inc. ...
IRS number
233079390
COR stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 24
8-K
Cencora Announces Common Share Repurchase from Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
24 May 24
8-K
Departure of Directors or Certain Officers
3 May 24
10-Q
2024 Q2
Quarterly report
1 May 24
8-K
Cencora Reports Fiscal 2024 Second Quarter Results
1 May 24
8-K
Entry into a Material Definitive Agreement
23 Apr 24
8-K/A
Departure of Directors or Certain Officers
15 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
8-K
Cencora Announces Leadership Succession Plan
12 Mar 24
8-K
1.05
27 Feb 24
Transcripts
COR
Earnings call transcript
2024 Q2
1 May 24
COR
Earnings call transcript
2023 Q3
2 Aug 23
COR
Earnings call transcript
2023 Q3
2 Aug 23
COR
Earnings call transcript
2023 Q2
2 May 23
COR
Earnings call transcript
2023 Q1
1 Feb 23
COR
Earnings call transcript
2022 Q3
3 Nov 22
COR
Earnings call transcript
2022 Q3
3 Aug 22
COR
Earnings call transcript
2022 Q2
4 May 22
COR
Earnings call transcript
2022 Q1
2 Feb 22
COR
Earnings call transcript
2021 Q4
4 Nov 21
Latest ownership filings
4
STEVEN H COLLIS
17 Jul 24
144
Notice of proposed sale of securities
16 Jul 24
4
Silvana Battaglia
5 Jul 24
4
Elizabeth S Campbell
5 Jul 24
4
Leslie E Donato
5 Jul 24
4
Leslie E Donato
2 Jul 24
4
STEVEN H COLLIS
20 Jun 24
144
Notice of proposed sale of securities
18 Jun 24
11-K
Annual report of employee stock purchases
13 Jun 24
4
Gina Clark
3 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn |
Cash burn (monthly) | 250.33 mm | (no burn) | (no burn) | (no burn) | 292.81 mm | (no burn) |
Cash used (since last report) | 967.99 mm | n/a | n/a | n/a | 1.13 bn | n/a |
Cash remaining | 1.32 bn | n/a | n/a | n/a | 1.15 bn | n/a |
Runway (months of cash) | 5.3 | n/a | n/a | n/a | 3.9 | n/a |
Institutional ownership, Q1 2024
97.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1094 |
Opened positions | 329 |
Closed positions | 100 |
Increased positions | 291 |
Reduced positions | 330 |
13F shares | Current |
---|---|
Total value | 41.82 tn |
Total shares | 194.35 mm |
Total puts | 4.27 mm |
Total calls | 4.93 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
WBA Walgreens Boots Alliance | 26.28 mm | $6.39 tn |
Vanguard | 20.35 mm | $4.94 tn |
BLK Blackrock | 19.20 mm | $4.66 tn |
T. Rowe Price | 8.99 mm | $2.18 bn |
STT State Street | 7.92 mm | $1.92 tn |
FMR | 5.46 mm | $1.33 tn |
Wellington Management | 5.02 mm | $1.22 tn |
JPM JPMorgan Chase & Co. | 4.94 mm | $1.20 tn |
Boston Partners | 4.12 mm | $1.00 tn |
Geode Capital Management | 3.92 mm | $949.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jul 24 | Collis Steven H | Common Stock | Sell | Dispose S | No | Yes | 222.12 | 10,755 | 2.39 mm | 285,088 |
16 Jul 24 | Collis Steven H | Common Stock | Option exercise | Acquire M | No | No | 89.58 | 10,755 | 963.43 k | 295,843 |
16 Jul 24 | Collis Steven H | NQSO Common Stock | Option exercise | Dispose M | No | No | 89.58 | 10,755 | 963.43 k | 75,281 |
1 Jul 24 | Donato Leslie E | Common Stock | Payment of exercise | Dispose F | No | No | 233.53 | 533 | 124.47 k | 9,457.849 |
1 Jul 24 | Donato Leslie E | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,432 | 0.00 | 9,990.849 |
1 Jul 24 | Donato Leslie E | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,432 | 0.00 | 0 |
28 Jun 24 | Donato Leslie E | Common Stock | Grant | Acquire A | No | No | 191.505 | 66.879 | 12.81 k | 9,524.728 |
28 Jun 24 | Elizabeth S Campbell | Common Stock | Grant | Acquire A | No | No | 191.505 | 57.902 | 11.09 k | 8,304.322 |
28 Jun 24 | Battaglia Silvana | Common Stock | Grant | Acquire A | No | No | 191.505 | 66.277 | 12.69 k | 12,421.08 |
News
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
17 Jul 24
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
12 Jul 24
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
9 Jul 24
A Closer Look at 4 Analyst Recommendations For Cencora
9 Jul 24
Baird Maintains Outperform on Cencora, Raises Price Target to $285
9 Jul 24
Press releases
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
8 Jul 24
Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release
5 Jul 24
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
22 May 24
Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds
22 May 24
Cencora Reports Fiscal 2024 Second Quarter Results
1 May 24